# Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

> **NCT01899326** · NA · TERMINATED · sponsor: **Albert Einstein College of Medicine** · enrollment: 10 (actual)

## Conditions studied

- DS (Durie/Salmon) Stage I Plasma Cell Myeloma
- DS Stage II Plasma Cell Myeloma
- DS Stage III Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Desipramine Hydrochloride
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01899326
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was stopped during the interim analysis due to low accrual after the widespread use of plerixafor for multiple myeloma in the United States.
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01899326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01899326, "Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01899326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*